A single-center retrospective cohort study published in the Journal of Immunotherapy and Precision Oncology evaluated 54 patients with stage II–III triple-negative breast cancer (TNBC) and documented germline BRCA status who received the KEYNOTE-522 pembrolizumab-based neoadjuvant chemoimmunotherapy regimen between January 2021 and December 2023. The cohort included 11 patients with germline BRCA mutations (BRCA+) and 43 without germline BRCA mutations (BRCA−). Patients in the BRCA+ group were younger than those in the BRCA− group (median age 38 vs 46 years; p=0.018).

Pathologic complete response (pCR) was achieved in 60% of evaluable patients overall and was numerically higher among BRCA+ patients than BRCA− patients (73% vs 56%; p=0.49). After a median follow-up of 25 months, the 2-year recurrence-free survival (RFS) was 100% in BRCA+ patients and 75.4% in BRCA− patients, while the…